The Fellow on Call: The Heme/Onc Podcast
A podcast for hematology and oncology fellows and practitioners, offering bite-sized, simplified approaches to common clinical questions. Each episode covers fundamentals, core concepts, and management approaches driven by the latest evidence and expert opinion. The show aims to educate anyone interested in the field, from students to practicing physicians.
Episodes
Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP
This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be sure to check out episodes 155 and 156!Content: - ITP management in pregnancy - ITP management in a patient with new VTE
Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!Content: - What are options after steroids?- How to counsel patients on options? - Is the
Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management
This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis? Content: - Refresher on diagnosis of ITP- Response criteria - What warrants a hospital admission vs. outpatient management? - What is ou
Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series)
This week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help mak
Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing
Therapy, Maintenance, and Relapsed/Refractory SequencingThis week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practica
Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly
This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part one, we tackle two highly practical topics: the AQUILA trial and its real-world impl
Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)
In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss.If you haven’t done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engager
Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma (2026)
In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don’t want to miss. Content:- What are treatment options for pa
Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026)
This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the pati
Episode 148: Myeloma Series, Pt. 8- Transplant in Multiple Myeloma (2026)
Throughout this series, we have discussed that for eligible patients, the current standard of care is to take patients for autologous stem cell transplant as consolidation for their multiple myeloma. In this reboot episode, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to
Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)
This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial.Content:- What is the role of autologous stem cell transplant in the management of multiple myeloma? - How did we get to our current standards of care?- How is minimal residual disease (MRD) fitting into our treatment paradigm?**
Episode 146: Career Development Series-Choosing Your Ideal Mentor
This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this h
Episode 145: Myeloma Series, Pt. 6 - First line treatment of Multiple Myeloma (2026)
This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break down the data and how to help you practically approach your treatment planning for your patient with newly diagnosed multip
Episode 144: Myeloma Series, Pt. 5 - Myeloma Risk Stratification and Response Criteria (2026)
This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose. Many present-day studies also use “minimal residual disease” (MRD) testing. What does this mean? How do we use this?We go through all of this and more in this incredibly hi
Episode 143: Myeloma Series, Pt. 4 - Myeloma Pharmacology (2025)
We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmac
Episode 142: Myeloma Series, Pt.3 - Management of Smoldering Multiple Myeloma (2025)
The way that we think about smoldering multiple myeloma (SMM) has continued to see evolution in the plasma cell dyscrasia space. If this diagnosis portends a higher risk of developing multiple myeloma, how should we manage patients to prevent possible end-organ damage? Is it a one-size-fits-all approach or are there some patients who are higher risk for progression than others? We cover this and s
Episode 141: Myeloma Series, Pt.2 - Intro to MGUS and Smoldering Myeloma (2025)
In today’s episode, we continue our myeloma series, this time we’ll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!Content:- Defining MGUS- Discussing risk of progression of MGUS to MM- How to interpret free light
Episode 140: Myeloma Series, Pt.1 - Intro to Testing and MGUS (2025)
It’s been 3 years since our last myeloma series updates and the reality is, a lot has changed! Instead of releasing an updates episode, we are redoing our prior myeloma series to make sure that you, our listeners, can follow along the way you always have. In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for so
Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week’s conversation!Episode contents:-
Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do. Episode contents:- What is the front-line approach to management for localized follicular lymphoma?- What about diffuse disease in a patient who is asymptomatic? What is the front-line options th
Episode 136: Follicular Lymphoma Series, Pt. 1 - Introduction
This week, we kick off a new series, this time focusing on follicular lymphoma! This series will build on a lot of fundamentals that we discussed in our prior series. In this first episode, we start with an introduction to how to approach management of this disease.Episode contents:- What is the best approach to biopsy? - What is the differential for CD10+ cells on flow? - How is follicular lympho
Episode 135: VTE Series - Management of Antiphospholipid Antibody Syndrome
This week, we round out our discussion we started in our prior episode on APLS, this time focusing on management. Stick around until the end to hear Dan and Vivek battle it out about the optimal time to recommend APLS testing for your patients!If you have not done so already, we highly recommend you check out episode 134 (diagnosis of APLS) prior to jumping into this one!Episode contents:- What is
Episode 134: VTE Series - Diagnosis of Antiphospholipid Antibody Syndrome
This week, we continue our series focusing on venous thromboembolism. In this episode, we begin our discussion of antiphospholipid syndrome.Episode contents:- What is "antiphospholipid antibody syndrome"?- How do we make this diagnosis?- What is the optimal time to test for these antibodies? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?
Episode 133: VTE Series - Perioperative Anticoagulation Management and Emergent Reversal
This week, we discuss another set of high yield topic for anyone who cares for patients on anticoagulation - how to safely hold anticoagulation prior to a procedure and how to reverse the effects of the drug in the even of an emergent situation. We discuss our approach to how we discuss this with our patients and our medical colleagues! Dan also shares his dotphrases for your reference! Episode co
Episode 132: VTE Series- Approach to Hypercoagulable/Thrombophilia Testing
This week, we talk all about hypercoagulable testing - a very common referral in outpatient hematology. Who do we consider testing on? Who should we encourage not to test? We discuss this and more here. Episode contents:- What are situations in which to consider hypercoaguable testing? - What are situations to avoid doing so? **** Get paid to participate in market research surveys: https://affilia
Episode 131: VTE Series-Approach to workup and initial management
This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success!Episode contents:-What is venous thro
Episode 130: Testicular Cancer Series, Pt 4 - Role of Radiation Oncology
This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective.Episode contents:- What are important studies to send to radiation oncol
Episode 129: Testicular Cancer Series, Pt 3 - Disseminated and relapsed/refractory disease
This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven’t already!Episode contents:- A history lesson about how we developed our current risk stratification model - Our current treatm
Episode 128: Testicular Cancer Series, Pt 2 - Stage 1 and 2
This week, we continue on our testicular cancer journey, focusing on Stage 1 and 2 disease. If you haven’t done so, we highly recommend checking out Episode 127 for our overview of this disease!Episode contents:- What it the approach to stage 1 seminoma and non-seminoa? Radiation? Chemotherapy? Surgery? - What about stage 2 disease? - What are the pivotal trials that shape today's treatment landsc
Episode 127: Testicular Cancer Series, Pt 1 - Introduction
It’s time for another new series, this time focusing on Testicular Cancer. In this first episode, we lay the foundation for our future discussions and discuss the basics of Testicular Cancer.Episode contents:- What are germ cell tumors?- What are important tumor markers to monitor for germ cell tumors?- Seminoma vs. Non-seminoma- Staging of germ cell tumors- Overview of management****Get paid to p
Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease
This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving! Episode contents: - How do we define primary induction failure in AML
Episode 125: AML Series, Pt 11 - Treatment of patients unfit for intensive therapy
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.Episode contents: - How do we assess fitness for intensive AML?- What are options for patients who are unfit for intensive chemotherapy for AML?- What are important genetic mutations are important to check for?- What are the key trials that inform our management in this space? - How do we
Episode 124: AML Series, Pt 10 - Allogeneic transplant for AML
In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML. Episode contents: - What are the different conditioning regimens available? - How do we decide which regimen is optimal for our patients? - What is the r
Episode 123: AML Series, Pt 9 - Introduction to Allogeneic Transplant
In today’s episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar’s pearls of wisdom help make this confusing topic so much more a
Episode 122: AML Series, Pt 8 - AML Maintenance Therapies
This week, we continue our series focusing on acute myeloid leukemia. In this episode, we talk about maintenance therapies in AML.Episode contents: - A recap of cytarabine consolidation - Why do we do maintenance therapy?- What are hypomethylating agents and how do they work? - Important targeted agents that play a role in maintenance therapy ****This episode is sponsored by our Global Research Pa
Episode 121: AML Series, Pt 7 - AML Consolidation: Role of Allogeneic Transplant
This week, we continue our discussion on consolidation and maintenance therapies for AML, this time highlighting the role of allogeneic stem cell transplants. This episode builds on our prior episode, so if you have not listened to this just yet, we highly recommend doing so! Episode contents: - A recap on approach to AML consolidation - The role of allogeneic transplants - The role of MRD testing
Episode 120: AML Series, Pt 6 - AML Consolidation: Therapeutic Approaches
This week, we move to our next phases of therapy for AML, which are consolidation and maintenance. Be sure to check out our prior episodes for a discussion on initial workup and how we incorporate recurrent genetic abnormalities into how we think about AML. Check out figure 1 from this paper for a helpful diagram!Episode contents: - A recap on approach to AML treatment- Who do we consider for allo
Episode 119: AML Series, Pt 5 - AML Induction: Options for Upfront Therapy
This week, we round out our discussion regarding AML induction, this time focusing on the treatment options in the first line setting. We go through the various options, the dosing strategies, and the data behind them. Be sure to check out parts one and two of this three-part induction discussion, as we continue to build on these concepts! Also, if you have not done so, please do check out our hem
Episode 118: AML Series, Pt. 4 - AML Induction: Approach to Initial Management
In this week’s episode, we continue onto part two of our three-part discussion on AML induction, this week focusing on selecting our up-front regimen. Be sure to check out last week’s episode, as this one builds on that one. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - What is "7+3"? - H
Episode 117: AML Series, Pt. 3 - AML Induction: Definitions and Overview
In this week’s episode, we start our three-part discussion on AML induction, this week focusing on key definitions and an overview of treatment. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - What are "blasts"?- If there is concern for AML, then what? - Role of leukapheresis or cytoreducti
Episode 116: AML Series, Pt. 2 - MDS/AML Diagnosis and Risk Stratification
In this week’s episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - A review of what to look at on the bone marrow b
Episode 115: AML Series, Pt. 1 - CHIP, CCUS, ICUS, oh my!
This week, we kick off a new series focusing on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this first episode, we discuss the alphabet soup of premalignant hematologic conditions including CHIP, CCUS, and ICUS, before moving onto MDS and AML in future episodes.Episode contents: - What is CHIP vs. CCUS vs. ICUS?- What is the mechanism of hematopoiesis? - What is clonality?
Episode 114: Acute Promyelocytic Leukemia (REBOOT!)
By popular demand, our next series that we are excited to share with you is on MDS/AML! As we prepare for the release of the first episode next week, let’s throw it back to Episode 019 in our Heme/Onc Emergencies Series and talk about APL!Episode contents: - How do we diagnose APL? - What are characteristic findings of APL? - What is the acute management of this disease? ****Have some time and wan
Episode 113: Sickle Cell Series - “Double Duty: A Doctor's Story of Living with Sickle Cell Disease While Caring for Others”
This week, we have an INCREDIBLE episode for you. We welcome Titilope Fasipe, MD, PhD, who not only is the Co-Director of the Sickle Cell and Thalassemia Program at Texas Children’s and an Assistant Professor in the Department of Pediatrics at the Baylor College of Medicine, she herself also has sickle cell disease! Dr. Fasipe takes us through her life story, from childhood to now. Conducting
Episode 112: Sickle Cell Series - Chronic Management of Sickle Cell Disease
In this week’s episode, we discuss the management of sickle cell disease in the chronic setting. This is a follow up to episode 111 where we discussed acute management of SCD. And furthermore, this is also in addition to our prior discussion about long-term chronic complications from SCD in episode 110. We highly recommend checking out these prior episodes if you haven’t done so already!Contents:
Episode 111: Sickle Cell Series - Acute Management of Sickle Cell Disease
In this week’s episode, we discuss the management of acute complications of sickle cell disease including acute pain episodes and acute chest syndrome as well as a discussion of hyperhemolytic syndrome.Contents: - How to manage patients with sickle cell disease presenting for acute pain crises- How to approach management of acute chest syndrome- What is hyperhemolytic crisis?- What is splenic and
Episode 110: Sickle Cell Series - Chronic Complications in Sickle Cell Disease
In this week’s episode, we discuss chronic complications that can arise in patients with sickle cell disease. The reality is, that unless we have an outpatient clinic or rotate through an outpatient clinic, there is a small chance that we will come across many of these issues. However, screening for and managing these chronic complications can have significant implications on our patients’ lives.
Episode 109: Sickle Cell Series - Introduction to Sickle Cell Disease
It’s time for another new series, this time focusing on Sickle Cell Disease! In this first episode, we lay the foundation for our future discussions. This episode can be dense, but rest assured we will revisit these concepts and expand on them throughout the series. Contents: - What is hemoglobin? - What is the underlying problem in sickle cell disease genotypically? - Why is the presence of sickl
Episode 108: Colorectal Cancer Series, Pt. 10 - Metastatic Colorectal Cancer (Part 2)
This week, we round out our discussion on metastatic colorectal cancer, focusing on more targeted therapies for this disease. If you have not done so already, be sure to check out episode 107 for the first part of our metastatic colorectal cancer discussion.Contents: - What is the role of immunotherapy?- What is the role of BRAF inhibition?- Can we use HER2 targeted therapies? - What is the role o
Episode 107: Colorectal Cancer Series, Pt. 9 - Metastatic Colorectal Cancer (Part 1)
This week, we continue our discussion of colorectal cancer, turning our attention to metastatic disease, specifically for cancers without targetable mutations. If you have not done already, we highly recommend you check out episode 104 for our GI oncology pharmacology discussion!Contents: - What information do we need when we approach a new patient with metastatic colorectal cancer? - How did we g
New Fellow Bootcamp Series: When Anticoagulation Fails (part 2)
** Be sure to check out our rotation guide for more show notes and episodes organized by disease type: https://www.thefellowoncall.com/rotation-guides** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagra
New Fellow Bootcamp Series: When Anticoagulation Fails (pt. 1)
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: When anticoagulation fails, Part 1! [Originally episode 079]Content: - How to approach a "DOAC
New Fellow Bootcamp Series: HIT/HITT
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: Heparin-induced thrombocytopenia! [Originally episode 071]Contents: - What is HIT? How is this
New Fellow Bootcamp Series: Cord compression
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: Cord compression! [Originally episode 014]Contents: - Differential diagnosis- What is the acute
New Fellow Bootcamp Series: SVC Syndrome
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: Superior vena cava (SVC) syndrome ! [Originally episode 012]- What is the workup?- What is the
New Fellow Bootcamp Series: Metastatic Cancer of “Origin TBD”
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: Metastatic Cancer of “Origin TBD,” a common question that comes up on solid oncology consults!
New Fellow Bootcamp Series: ITP
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: immune thrombocytopenic purpura [Originally episode 015]Episode contents: - What is the workup for t
New Fellow Bootcamp Series: TTP
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. First up: thrombotic thrombocytopenic purpura (TTP) [Originally episode 018]Episode contents: - What is the w
Episode 106: Colorectal Cancer Series, Pt. 8 - Early Onset Colorectal Cancer
In a recent American Cancer Society publication, there are increasing data that rates of colorectal cancer are rising rapidly among people in their 20s, 30s and 40s. This has certainly caught the attention of the lay press, most recently in a widely circulated New York Times article published in March 2024. Today, we welcome Dr. Chris Cann, who is an Assistant Professor of Hematology/Oncology at
Episode 105: Colorectal Cancer Series, Pt. 7 - Management of Rectal Cancer
This week, we incorporate medical oncology back into our discussion with our Radiation Oncologist, Dr. Sanford, and our Surgical Oncologist, Dr. Bailey. We discuss how we approach the management of localized rectal cancer. Note that we will be heavily building off our discussions with our specialist. We recommend listening to these episodes if you have not done so already.Content: - What informati
Episode 104: Colorectal Cancer Series, Pt. 6 - Colorectal Cancer Pharmacology
We have another guest joining us this week! Dr. Allison Schepers, PharmD, BCOP is a Clinical Pharmacist Specialist at the Rogel Cancer Center at the University of Michigan where she focuses on GI, GU, and Thoracic malignancies! In this episode, Allison discusses the high yield points we need to know about important drugs we use in the colorectal cancer treatment space and how she approaches counse
Episode 103: Colorectal Cancer Series, Pt. 5 - Surgical Management of Colorectal Cancer
This week, we are joined by Dr. Christina Bailey, Associate Professor of Surgery and Program Director of the General Surgery Residency at Vanderbilt University Medical Center in Nashville, Tennessee, for a discussion about the role of surgery in the management of patients with colorectal cancer. This is another amazing multidisciplinary colorectal surgery episode you do not want to miss!Content: -
Episode 102: Colorectal Cancer Series, Pt. 4 - Role of Radiation Therapy in Colorectal Cancer Management
This week, we are joined by Dr. Nina Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center in Dallas, Texas, for a discussion about the role of radiation in colorectal cancer, with an emphasis on the role of radiation in rectal cancer. Dr. Sanford is a wealth of knowledge so this is an episode you do NOT want to miss. Of note, rectal
Episode 101: Colorectal Cancer Series, Pt. 3 - Adjuvant Therapy in Stage II Colon Cancer and ctDNA
In this week’s episode, we discuss the management of stage II colon adenocarcinoma, which is defined by a lack of nodal involvement and invasion through the muscularis layer of the colon. If you have not done so already, be sure to check out episode 099 (overview of colorectal cancer) and episode 100 for stage III colon cancer, as we will building on concepts discussed already. Content: - Is there
Episode 100: Colorectal Cancer Series, Pt. 2 - Adjuvant Therapy in Stage III Colon Cancer
This week, we kick off our discussion of adjuvant systemic treatment in colon cancer, beginning with Stage III colon cancer. We will review the evidence basis for adjuvant therapy as well as the two main chemotherapy regimens including duration and side effects. Content: - Why do we need adjuvant therapy in stage III colon cancer? - What is FOLFOX? What is CAPOX? When do we use what?- What is the
Episode 099: Colorectal Cancer Series, Pt. 1 - Intro to Colorectal Cancer
Colorectal cancer is one of the most common cancers diagnosed each year worldwide. This highly anticipated series will take an in-depth look at this disease. In this first episode, we discuss the basics, including staging, tumor markers, and microsatellite instability testing, before tackling the management of colorectal cancer in upcoming episodes. Content: - What is the incidence of colorectal c
Episode 098: Understanding MRD Testing in CLL
With multiple options for frontline therapy in CLL, MRD has the potential to emerge as a factor that could be considered in our decision-making algorithm for sequencing treatment options. In this week’s episode, we dive into a deeper understanding of the role of MRD testing in CLL. Content: - What is the role of MRD testing in CLL?- What are the techniques we use to evaluate for MRD?- What is the
Episode 097: Treatment of Relapsed/Refractory CLL
This week, we continue our discussion of treatment of CLL, this time focusing on the relapsed/refractory CLL. If you have not done so, we recommend checking out our prior episodes since we will be building on these conversations! Content: -If you suspect your patient has relapsed, what do you do? -What is the approach to treatment in the relapsed/refractory setting?- What is Richter's transformat
Episode 096: Treatment of CLL
We continue on our journey through chronic lymphocytic lymphoma (CLL), this time focusing our attention to the treatment of CLL. Content: - What are the indications for treatment?- Can I wait to treat and not impact OS?- What is our current approach to treatment ? - Fixed duration vs. indefinite treatment options?** Want to review the show notes for this episode and others? Check out our webs
Episode 095: Introduction to CLL/SLL
This week, we start a new series, this time all about the ins-and-outs of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)! Whether practicing general internal medicine, hospital medicine, or hematology/oncology, you will likely come across a patient with CLL. First, we go through initial diagnosis of this disease! Content: - What is CLL? How is this different than SLL?- What
Episode 094: Heme Consult Series: Cold Agglutinin Disease
In this week’s episode, we finish our series on hemolytic anemias with a discussion on cold agglutinin disease along with a few other causes of acquired hemolytic anemia.Content: - What is "cold agglutinin disease"?- Why is it called "cold"?- How do we diagnose this disease?- How do we treat? - BONUS: What are some other examples of hemolysis? ** Want to review the show notes for this episode and
Episode 093: Heme Consult Series: Warm Autoimmune Hemolytic Anemia
Next in our heme consult series is all about the workup and management of warm autoimmune hemolytic anemia (wAIHA), a very scary situation! These patients can often be very sick and there can be a lot of underlying issues that may be causing this to occur. Rest assured- after this episode, you’ll be a pro at identifying this disorder and know how to manage it should you ever come across this. If y
Episode 092: Heme Consult Series: Congenital Causes of Hemolytic Anemia
In the next part of this heme consult series, we discuss several congenital causes of hemolytic anemias. These diseases are relatively rare, but in patients presenting with concerns for hemolysis on history and on labs, but with a negative DAT, it is important to have these in your differential diagnosis! We take you through how to think about these disorders, their diagnosis, and management. If y
Episode 091: Heme Consult Series: Intro to Acquired Hemolytic Anemia and G6PD Deficiency
It’s time for another heme consult series, this time focusing on hemolytic anemias. In this multi-part series, we will go through our approach to thinking about concerns for hemolytic anemias. This is super high yield for anyone who cares for patients, especially those in hematology/oncology. It’s not uncommon to get a consult on the heme consult service for assistance with diagnosis and managemen
Episode 090: Prostate Cancer Series, Pt. 7- Treatment for Met. Castrate Resistant Prostate Cancer
We made it to the end of another series. In our FINAL episode of the prostate cancer series, we turn our attention to metastatic castrate-resistant prostate cancer! We discuss treatment options, the data behind why we do what we do, and more targeted agents.Content: - Approach to metastatic castrate-resistant prostate cancer- Refresher on what it means to be castrate-resistant - Role of bisphospha
Episode 089: Prostate Cancer Series, Pt. 6- Treatment for Met. Castrate Sensitive Prostate Cancer
This week, we continue our discussion about metastatic castrate sensitive prostate cancer. Spoiler alert: there is not good guidance or biomarkers that help us pick one regimen over another. In this episode, we go through the data, our critical appraisal of the data, and some things to consider when selecting one regimen over another. As a refresher, be sure to check out our Pharmacology Epis
Episode 088: Prostate Cancer Series, Pt. 5 - Systemic Treatment for Localized Prostate Cancer
As we continue our exploration of prostate cancer, we turn our focus to one of the earliest areas where medical oncologists are commonly involved: systemic therapy for non-metastatic prostate cancer. In this episode, we will review how to risk stratify localized prostate cancer, differences in FDA-approved prostate-specific PET tracers, how to evaluate for biochemical recurrence following surgical
Episode 087: Prostate Cancer Series: Pt. 4- Radiation Oncology in Prostate Cancer
Last, but not least, in our multidisciplinary discussions regarding the management of prostate cancer, we are thrilled to present a special episode featuring soon-to-be attending Radiation Oncologist Dr. Jacob Hall. Dr. Hall is a senior Radiation Oncology resident and Chief Resident at UNC-Chapel Hill. Today, he helps us better understand patient selection for radiation and helps define key terms.
Episode 086: Prostate Cancer Series: Pt. 3- Surgical Approaches to Prostate Cancer
In our next episode, we are joined by Dr. Sanjay Patel, a urologic oncologist from the Stephenson Cancer Center at the University of Oklahoma, who also happens to be Vivek’s older brother! We discuss the management of prostate cancer from the perspective of our urology colleagues. As medical oncologists, these are conversations and decisions that we are almost never a part of, as they are being ha
